A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
This is a dose-ranging study designed to investigate the efficacy and safety of Baricitinib
in the treatment of participants with moderate to severe, chronic plaque psoriasis as
assessed by the Psoriasis Area and Severity Index (PASI) score and routine safety
assessments.